Potential role of leukotriene receptor antagonists in reducing cardiovascular and cerbrovascular risk: A systematic review of human clinical trials and in vivo animal studies - 25/08/18
, Anne-Mary Lewis-Mikhael c, Aurora Bueno-Cavanillas d, e, fBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 10 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Graphical abstract |
Highlights |
• | Leukotrienes receptor antagonist (LTRA) use was associated with a reduction of infarct size volume or attenuation of neurological deficits. |
• | Possible mechanism of action of LTRA were reported, such as the reduction of oxidative stress and apoptotic markers. |
• | LTRA were associated with a cardio protective effect against myocardial injury in animals. |
• | There is a potential role of montelukast in reducing some cardiovascular diseases in human clinical trials. |
Abstract |
Background |
Leukotrienes are important lipid mediators of inflammation arising from arachidonic acid cascade. They are implicated in vascular inflammation and produced in different pathologic conditions as atherosclerosis, stroke and myocardial infarction. Different studies have investigated the role of leukotriene receptor antagonist (LTRA) in reducing some cardiovascular events, especially in animals. We conducted a systematic review of both in vivo animal and human studies to determine the potential role of leukotriene receptor antagonist in reducing cardiovascular and cerebrovascular events.
Methods |
Data sources: Pubmed, Embase and Cochrane database. Data extraction: Two reviewers independently screened potentially eligible articles and extracted relevant data.
Results |
A total of 28 studies were included, of which 26 were conducted in animals, and 2 in humans.
Conclusions |
All animal studies reported that using a leukotriene receptor antagonist brings to a reduction of either myocardial infarction, ischemic stroke, or atherosclerosis risk. Similar results were obtained from two clinical trials on humans, suggesting a potential role of montelukast in reducing some cardiovascular diseases.
Le texte complet de cet article est disponible en PDF.Abbreviations : AA, CV, CysLTs, CysLTR, LT, LTRA
Keywords : Leukotriene receptor antagonist, Montelukast, Cardiovascular event, Cysteinyl leukotrienes, Ischemic stroke
Plan
Vol 106
P. 956-965 - octobre 2018 Retour au numéro
Article précédent
- Role of oxidative stress in pathology of chronic prostatitis/chronic pelvic pain syndrome and male infertility and antioxidants function in ameliorating oxidative stress
- Awais Ullah Ihsan, Farhan Ullah Khan, Puregmaa Khongorzul, Khalil Ali Ahmad, Muhammad Naveed, Sufia Yasmeen, Yanfang Cao, Abdoh Taleb, Richinandan Maiti, Fahad Akhter, Xiaoqian Liao, Xue Li, Yijie Cheng, Hidayat Ullah Khan, Khurshid Alam, Xiaohui Zhou
- Diabetes and hepatocellular carcinoma: A pathophysiological link and pharmacological management
- Mandeep Kumar Singh, Bhrigu Kumar Das, Sandeep Choudhary, Deepak Gupta, Umesh K Patil
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?